Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Study of Fosrolapitant and Palonosetron for the Prevention of Nausea and Vomiting Induced by Antibody-Drug Conjugates in Cancer Patients

NCT07692451 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT07692451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07692451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Study of Fosrolapitant and Palonosetron for the Prevention of Nausea and Vomiting Induced by Antibody-Drug Conjugates in Cancer Patients
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 15, 2026
Completion date
September 30, 2027
Enrollment
124 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nausea and vomiting induced by antibody-drug conjugates (adcs)